SecBot SecBot
SECBOTREPLAY Home › Report › HRTX

HRTX · Asset sale to CorMedix for $223M

Heron Therapeutics, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 07:15 ET

At the news

MIXEDIMPACT 7/10

PRESS-RELEASE filed Nov 9, 2026 at 07:15 ET

CorMedix (CRMD) will acquire substantially all of Heron Therapeutics' (HRTX) assets for $145M cash plus 14.6M CRMD shares (worth ~$77.6M at signing), plus up to $55M in earn-outs and royalties. The deal adds four commercial-stage hospital products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) to CorMedix's institutional platform. Heron will remain a public company with CRMD stock, NOLs (~$2.3B), and earn-out rights, while repaying its Hercules credit facility. The transaction is expected to close in Q1 2027.

  • Upfront consideration: $145M cash plus 14,583,333 shares of CorMedix common stock (fixed at $7.20/share, valued at ~$77.6M at CRMD's $5.32 closing price on Nov 6, 2026), aggregate ~$222.6M
  • Additional earn-out: up to $55M tied to ZYNRELEF 2028 net sales ($25M if ≥$65M, +$30M if ≥$95M)
  • 5% royalty on combined annual net sales of CINVANTI, SUSTOL, and licensed products exceeding $25M in 2027-2029
  • CorMedix expects $45-$60M in near-term operating cost synergies by year-end 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access